Inferior STEMI complicated by retroperitoneal hemorrhage due to
ruptured AAA
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Abstract
When patients present with life threatening conditions, a rapid cost-benefit analysis prioritizes
care and commits treatment to a certain course that, in the case of ST Elevation Myocardial
Infarction (STEMI) treated with drug-eluting stents (DES), could be fatal if there is any
deviation. Antiplatelet therapy is vital and secondary concerns (i.e. bleeding diatheses) may
accept suboptimal outcomes – in rare cases, another life-threatening condition may be unmasked,
the treatment for which runs directly counter to the first. We present a case of STEMI with high
clot burden treated with multiple DES, complicated by retroperitoneal hemorrhage due to a
ruptured abdominal aortic aneurysm.
Keywords
STEMI, retroperitoneal hemorrrhage, abdominal aortic aneurysm, anticoagulation
Introduction
A 68 year old Caucasian male with a past medical history of coronary artery disease (CAD) and
prior myocardial infarction treated with percutaneous coronary intervention (PCI), Vfib arrest,
hypertension, hyperlipidemia, smoking and COPD presented to the emergency department
following two hours of chest pain - EKG on admission revealed inferior Q waves and ST
elevation. After initiation of heparin bolus and drip, he was taken for emergent left heat
catheterization via right femoral access which revealed the culprit lesions to be a 90% proximal
right coronary artery (RCA) stenosis with thrombus and 60-70% in-stent restenosis (ISR). He
received Xience Alpine 3.5x9mm and 3.0x12mm drug-eluting stents (DES) to his proximal
RCA, and Xience alpine 3.0x12mm and 3.0x38mm DES to his mid-RCA.

Figure A: left coronary system, AP
projection

Figure B: Right coronary system,
LAO projection

He tolerated the procedure well and was transferred to the CCU on aspirin, Plavix and Integrilin,
due to the thrombus burden. Six hours later, he began complaining of abdominal discomfort and
received IV morphine and IV Dilaudid. He was then noted to have downward trending blood
pressures – fluids were initiated, and due to concern for retroperitoneal hemorrhage, CT
abdomen was ordered. In addition to a large retroperitoneal hematoma, CT revealed a ruptured
infra-renal abdominal aortic aneurysm (AAA) 9.1cm antero-posterior by 8.7cm transverse by
12.1 cm in length, with interior features concerning for intramural hematoma vs. underlying
dissection.

Figures C and D: Abdominal Aortic Aneurysm
An emergent call was placed to cardiothoracic / vascular surgery, and the patient was
immediately evaluated. A brief discussion revealed that there was no graft available large enough
for an endovascular repair (EVAR), and he was taken to the OR for emergent open AAA repair.
During the procedure he was found to have thrombus and plaque within the aneurysm cavity
with complete posterior and left lateral aneurysmal tear, and a 16mm Hemashield graft was used
for the repair. Hemoglobin (Hb) on admission trended down from 11.5 to 9.7 immediately prior
to the OR, he was transfused to a hemoglobin of 11.2, and this trended down to a nadir of 7.3
four days post-surgery. Dual antiplatelet therapy was by necessity continued, and he was again
transfused, for a total of 8 units. Repeat CT abdomen revealed significant improvement in
retroperitoneal hemorrhage, though he was found to be positive for fecal occult blood. He was
evaluated by gastroenterology, upper endoscopy the following day revealed gastritis and a nonbleeding gastric ulcer, and he was started on a proton pump inhibitor. The rest of the patient’s
hospital course was complicated by atrial tachycardia, acute kidney injury, and confusion, all of
which resolved with appropriate treatment. He was evaluated by physical therapy and inpatient
rehab was recommended, though the patient declined and was ultimately discharged in good
health, with Hb over 8. He did not keep his follow-up visit with cardiology.

Discussion
“There is no disease more conducive to clinical humility than aneurysm of the aorta.”
- Sir William Osler
More remarkable than this patient’s clinical course is the fact that he survived to discharge. Heart
disease is responsible for 1 in 4 deaths in the US, claiming 670,000 lives - 61% of which are
attributable to coronary heart disease.1 Although this patient presented as a STEMI, it was in his
favor that he was not in cardiogenic shock and didn’t require mechanical support. However, his
stent placement was not without subsequent risk; one review found that with ideal compliance
with dual antiplatelet therapy (DAPT), the incidence of definite stent thrombosis at 3 years was
1% with 2nd generation DES, 1.5% with bare metal stents (BMS) and 2.2% with first generation
DES.2 Though the updated recommendations on the duration of antiplatelet therapy following
stent placement were relaxed to a minimum of 6 months in stable ischemic heart disease, it
remains a class I recommendation to continue DAPT for a minimum of 12 months in the setting
of acute coronary syndromes.3 A meta-analysis found that the risk of stent thrombosis was
highest in the setting of extensive CAD, early discontinuation of DAPT, and number of stents4 with these risk factors alone, the patient was already at higher risk for a negative outcome.
Patients frequently experience post-catheterization groin or back discomfort, though it was this
patient’s downward trending blood pressure that ultimately revealed the cause of his discomfort.
Retroperitoneal hemorrhage (RPH) is a feared complication of cardiac catheterization via
femoral access, with prevalence ranging from 0.4% to 0.74%.5-7 Features include groin pain in
42-100%, back pain in 23-64%, and hypotension in 92%. Female gender, low body surface area,
and high arterial puncture are recognized risk factors; one review found no association between
RPH and sheath size, GpIIb/IIIa inhibition, and use of a closure device 5, though others have
shown a link between sheath size and use of closure device 7. RPH is associated with high inhospital mortality (6.64% vs. 1.07%) in those without RPH, due in part to the often insidious
presentation.7 The majority of patients (84-92.3%) with RPH are treat medically, with few
requiring surgery5,7, though placement of a covered stent is an acceptable treatment with
favorable anatomy. In one review the average drop in hemoglobin among patients with RPH was
11.5 +5¸compared with 2.3+ 3.3 in controls.6 The previous statistics cannot apply to this patient,
however; his RPH was determined to be due to his ruptured AAA, which carried a far more
dismal prognosis.
Patients with CAD are often at risk for AAA; one review found the incidence of AAA in patients
over 60 with CAD to be 14%, as compared to 3% in patients without CAD.8 Smoking was found
to be a strong risk factor for not only AAA development but also rupture9, though diabetes
mellitus was found to be negatively associated with AAA. The USPSTF recommends a one-time
screening abdominal ultrasound in men between the ages of 65 and 75 who have ever smoked,
with a class B recommendation (strong evidence that the effect is moderate, or moderate effect
that the evidence is strong) .10 The prevalence of AAA is estimated to be 1.3% in women and 5-

9% in men over 6511,12, with mortality due to ruptured AAA as high as 90%13, making ruptured
AAA the 13th leading cause of death in the western world as of 200514. Further complicating
matters, open AAA repair is associated with a 53% mortality, compared to 24% with
endovascular aneurysm repair (EVAR).15
The conflict at the crux of this patient’s care was the aggressive anticoagulation necessary to
maintain patency of multiple drug-eluting stents, and the effect of that anticoagulation on his
potentially catastrophic AAA. Did the LHC contribute to aneurysmal rupture? It is certainly a
possibility; advancement of the catheters could have caused trauma to an already friable
endothelium. Nevertheless, the patient was already at risk prior to his LHC. Application of
Laplace’s law to aneurysms (increasing wall tension with increasing diameter) has been found to
be faulty due to aneurysm wall heterogeneity, with different segments of the aneurysmal wall
experiencing different wall stress – thus, smaller aneurysms area also at risk of rupture.14
However, the recommendation for repair at 5cm is due to the increased likelihood of rupture,
with a 32.5% 1 year incidence of rupture for AAA >7cm.16 Thus, it is entirely possible that this
patient’s AAA had been slowly bleeding prior to his STEMI, and that the administration of
aspirin, Plavix, and Integrilin hastened the process. Essentially, the only options were either to
discontinue all antiplatelet / anticoagulant medications in favor of reducing bleeding from the
AAA, or to continue DAPT and hope for the best, with the former option having been
determined to have worse early and late outcomes than the latter. Ultimately, despite continued
DAPT, the patient’s bleeding abated and his surgical site remained stable - even his subsequent
GI bleed required no intervention. The close communication between interventional cardiology
and cardiothoracic / vascular surgery led to decisive, timely treatment, setting the stage for an
optimal outcome against overwhelming odds.
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